GlassScriptPhysician profile
Daryl A Ellis
NPI 1467468355
$3,045.89
in general payments reported to CMS, 2019-2025
25 companies · $66.94 in 2025
The $66.94 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,578 · 2020: $633 · 2021: $321 · 2022: $85.62 · 2023: $152 · 2024: $209 · 2025: $66.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $428.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $475.04 | 2019-2021 | |
| Novo Nordisk INC | $449.23 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $420.57 | 2019-2025 | Airsupra, Farxiga |
| Sanofi-Aventis U.S. LLC | $353.09 | 2019-2024 | |
| Astellas Pharma US INC | $262.75 | 2019-2023 | Veozah |
| Lilly USA, LLC | $178.32 | 2019-2024 | Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $116.88 | 2019-2020 | |
| Allergan, INC. | $108.36 | 2019-2020 | |
| Abbvie INC. | $105.65 | 2020-2024 | |
| Glaxosmithkline, LLC. | $77.34 | 2019-2023 | Trelegy Ellipta |
| Amgen INC. | $63.08 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $54.49 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $51.68 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.34 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.02 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $42.97 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $41.55 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $26.38 | 2019-2021 | |
| Verona Pharma, INC. | $25.34 | 2025 | Ohtuvayre |
| Supernus Pharmaceuticals, INC. | $22.32 | 2019 | |
| Nevro Corp. | $20.05 | 2021 | |
| Abbott Laboratories | $19.62 | 2022 | |
| Roche Diabetes Care, INC. | $13.77 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.25 | 2019 | |
| Amarin Pharma, INC. | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daryl Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.